RI-MUHC team takes another step toward precision medicine by targeting a biomarker of CDK4/6 inhibitor efficacy in breast cancer, including triple-negative breast cancer
https://muhc.ca/news-and-patient-stories/news/triple-negative-breast-cancer-new-hope-existing-drug